Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191587 | 0.93 | FAAH (0.37) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL22024007 | 0.93 | CTDSP1 (0.35) | FAAHCTDSP1 | |
| SCHEMBL21478368 | 0.92 | FAAH (0.39) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL21124081 | 0.90 | FAAH (0.40) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL21191736 | 0.90 | FAAH (0.40) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL21191567 | 0.90 | FAAH (0.40) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL22023632 | 0.90 | FAAH (0.40) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL22024455 | 0.84 | FAAH (0.38) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL22023840 | 0.84 | FAAH (0.38) | FAAHCTDSP1TDP1L3MBTL1 | |
| SCHEMBL28610775 | 0.80 | FAAH (0.34) | FAAHTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | FAAH 1387/4885CTDSP1 1925/4885TDP1 534/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | FAAH 3447/4885CTDSP1 430/4885TDP1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.